Alkem Laboratories Limited has informed the Exchange that Board of Directors at its meeting held on February 13, 2026, declared Interim Dividend of Rs. 43 per equity share.
ALKEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 6.1 pts less than Nifty Midcap 150 and 6.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The Board of Alkem Laboratories, at its meeting on February 13, 2026, declared an interim dividend of Rs. 43 per equity share (2,150% on the face value of Rs. 2) for FY 2025-26. The record date is February 20, 2026, and dividend payment will commence from March 6, 2026. The company also approved its Q3 FY26 financial results: consolidated revenue from operations stood at Rs. 37,368.2 million (up about 10.7% year-on-year) with a net profit of Rs. 6,530.3 million. For the nine months ended December 2025, consolidated revenue grew 13.1% YoY to Rs. 111,089.5 million and net profit was Rs. 21,000.5 million. Standalone Q3 revenue was Rs. 24,912.7 million with a net profit of Rs. 6,221.4 million. Exceptional items of Rs. 527.9 million (consolidated) were booked, mainly related to the new Labour Codes notified in November 2025. Q3 EPS came in at Rs. 53.19 (consolidated).
Shareholders holding Alkem shares on or before February 20, 2026 are eligible for the Rs. 43 per share interim dividend, payable from March 6, 2026. The double-digit revenue growth along with a hefty interim dividend signals strong financial health and is generally positive for the stock, though the one-time Labour Code provision modestly weighed on quarterly profit.